Marekani - Kiingereza - NLM (National Library of Medicine)

reckitt benckiser llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 2 g in 100 ml - acne medication for the treatment of acne

Marekani - Kiingereza - NLM (National Library of Medicine)

rb health (us) llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 2 g in 100 ml - acne medication for the treatment of acne

Marekani - Kiingereza - NLM (National Library of Medicine)

rb health (us) llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 2 g in 100 ml - acne medication for the treatment of acne

Marekani - Kiingereza - NLM (National Library of Medicine)

reckitt benckiser llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 2 g in 100 ml - acne medication for the treatment of acne

Marekani - Kiingereza - NLM (National Library of Medicine)

zo skin health, inc. - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 20 mg in 1 ml - acne treatment - for the management of acne. - penetrates pores to control acne blemishes.

Marekani - Kiingereza - NLM (National Library of Medicine)

zo skin health, inc. - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 20 mg in 1 ml - acne treatment - for the management of acne. - penetrates pores to control acne blemishes.

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - acetylsalicylic acid 100 mg - gastro-resistant tablet - 100 mg - acetylsalicylic acid 100 mg - acetylsalicylic acid

Marekani - Kiingereza - NLM (National Library of Medicine)

acella pharmaceuticals, llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - indications and usage for dermatologic use: salicylic acid 6% foam is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae and the various ichthyoses, keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris and psoriasis. for podiatric use: salicylic acid 6% foam is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. contraindications salicylic acid 6% foam should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. salicylic acid 6% foam should not be used in children under 2 years of age.

Singapoo - Kiingereza - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (acetylsalicylic acid layer) acetylsalicylic acid (as acetylsalicylic acid granulated with starch); (clopidogrel layer) clopidogrel (as clopidogrel hydrogen sulfate form ii) - tablet, film coated - 100 mg - (acetylsalicylic acid layer) acetylsalicylic acid (as acetylsalicylic acid granulated with starch) 100 mg; (clopidogrel layer) clopidogrel (as clopidogrel hydrogen sulfate form ii) 75 mg

Marekani - Kiingereza - NLM (National Library of Medicine)

jacobus pharmaceutical company, inc. - aminosalicylic acid (unii: 5b2658e0n2) (aminosalicylic acid - unii:5b2658e0n2) - aminosalicylic acid 4 g - paser is indicated for the treatment of tuberculosis in combination with other active agents. it is most commonly used in patients with multi-drug resistant tb (mdr-tb) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. when paser is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible. hypersensitivity to any component of this medication. severe renal disease. patients with severe renal disease will accumulate aminosalicylic acid and its acetyl metabolite but will continue to acetylate, thus leading exclusively to the inactive acetylated form; deacetylation, if any, is not significant. the half life of free aminosalicylic acid in renal disease is 30.8 minutes in comparison to 26.4 minutes in normal volunteers. but the half life of the inactive metabolite is 30